The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

计划入组 65 人 · 首次发布于 2015 年 10 月 27 日

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

计划入组 132 人 · 首次发布于 2011 年 5 月 9 日

The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

计划入组 208 人 · 首次发布于 2015 年 10 月 12 日

TMPRSS2-ERG fusion gene therapy

ERG-344

ERG-245

Eneco Refresh Ltd

Berg LLC

United States

NRG Oncology

United States

Parabilis Medicines Demonstrates First-Ever Degradation of ERG in Prostate Cancer Models

Pro-Neuropeptide Y Emerges as a Circulating Biomarker for Poor Prognosis in Prostate Cancer

BostonGene Presents Six AI-Driven Cancer Research Studies at 2025 ASCO Annual Meeting